Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Q2 2023 Results Conference Call August 8, 2023 8:30 AM ET

Company Participants

Allison Wey - Senior Vice President of Investor Relations

Paul Edick - Chairman and Chief Executive Officer

Steven Pieper - Chief Financial Officer

Conference Call Participants

Oren Livnat - H. C. Wainwright

Glen Santangelo - Jefferies

Operator

Good morning all. I would like to welcome you all to Xeris Biopharma Second Quarter 2023 Financial Results Call. My name is [Prika], and I will be your moderator for today’s call. All lines are on mute for the presentation portion of the call today with an opportunity for questions and answers at the end. [Operator Instructions]

I would now like to pass the conference over to your host, Allison Wey, Senior Vice President of Investor Relations and Corporate Communications to begin. So Allison, please go ahead.

Allison Wey

Thank you, Prika. Good morning and welcome to Xeris Biopharma second quarter financial results conference call and webcast. A press release with the company’s financial results was issued earlier this morning and can be found on our website.

We are joined this morning by Paul Edick, Chairman and CEO; and Steve Pieper, CFO. Paul will provide opening remarks, Steve will provide details on our financial results, then we will open the call for Q&A.

Before we begin, I would like to remind you that, this call will contain forward-looking statements, which may include but are not limited to statements concerning our business practices, future expectations, plans, prospects, clinical approvals, commercialization, corporate strategy and performance, which constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995.

Actual results may differ materially from those indicated by these forward-looking statements made during this call, as a result of various factors, including our financial position and need for financing including to fund our product development programs or commercialization efforts.

Whether our products will achieve and maintain market acceptance in a competitive business environment. Our reliance on third-party suppliers, including single-source suppliers, our reliance on third-parties to conduct clinical trials. The ability of our product candidates to compete successfully with existing and new drugs, adverse effects of macroeconomic conditions on our business operations and clinical activities, and our and our collaborators ability to protect our intellectual property and proprietary technology, as well as other risk factors set forth in our filings with the Securities and Exchange Commission.